- Home
- MODD vs IKNA Comparison
MODD vs IKNA Comparison
Compare MODD & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- IKNA
- Stock Information
- Founded
- MODD 1998
- IKNA 2016
- Country
- MODD United States
- IKNA United States
- Employees
- MODD N/A
- IKNA N/A
- Industry
- MODD Industrial Specialties
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- IKNA Health Care
- Exchange
- MODD Nasdaq
- IKNA Nasdaq
- Market Cap
- MODD 46.3M
- IKNA 52.1M
- IPO Year
- MODD N/A
- IKNA 2021
- Fundamental
- Price
- MODD $0.85
- IKNA $1.18
- Analyst Decision
- MODD
- IKNA Buy
- Analyst Count
- MODD 0
- IKNA 2
- Target Price
- MODD N/A
- IKNA $3.00
- AVG Volume (30 Days)
- MODD 78.5K
- IKNA 109.0K
- Earning Date
- MODD 06-20-2025
- IKNA 05-08-2025
- Dividend Yield
- MODD N/A
- IKNA N/A
- EPS Growth
- MODD N/A
- IKNA N/A
- EPS
- MODD N/A
- IKNA N/A
- Revenue
- MODD N/A
- IKNA N/A
- Revenue This Year
- MODD N/A
- IKNA N/A
- Revenue Next Year
- MODD N/A
- IKNA N/A
- P/E Ratio
- MODD N/A
- IKNA N/A
- Revenue Growth
- MODD N/A
- IKNA N/A
- 52 Week Low
- MODD $0.68
- IKNA $0.97
- 52 Week High
- MODD $2.65
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- MODD 36.37
- IKNA 53.94
- Support Level
- MODD $0.75
- IKNA $1.10
- Resistance Level
- MODD $0.90
- IKNA $1.20
- Average True Range (ATR)
- MODD 0.07
- IKNA 0.08
- MACD
- MODD -0.01
- IKNA 0.01
- Stochastic Oscillator
- MODD 29.09
- IKNA 74.70
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.